Notice for avacopan (Vifor Pharma Pty Ltd)
Active ingredients
avacopan
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Hard capsule
Indication
Tavneos, in combination with other immunosuppressant therapies, is indicated for the treatment of patients with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA])
Therapeutic area
Immunology